Using a cannabinoid to relieve itching and inflammation in dermatomyositis
A nonpsychoactive cannabinoid receptor-2 agonist to treat itch and inflammation in dermatomyositis
['FUNDING_R01'] · UNIVERSITY OF PENNSYLVANIA · NIH-10656390
This study is looking at a new treatment that could help reduce the severe itching and inflammation caused by dermatomyositis, an autoimmune disease, and it's designed for people who are dealing with this condition.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PENNSYLVANIA (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-10656390 on ClinicalTrials.gov |
What this research studies
This research investigates the use of a nonpsychoactive cannabinoid receptor-2 agonist to alleviate severe itching and inflammation associated with dermatomyositis, an autoimmune disease. The study builds on previous successful trials that showed improvements in skin disease activity and quality of life for patients. By examining the effects of this treatment on immune cell activity in the skin, the research aims to provide a safer and more effective therapy for patients suffering from this condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with dermatomyositis who experience severe itching and skin inflammation.
Not a fit: Patients with dermatomyositis who do not experience significant itching or inflammation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that significantly improves the quality of life for patients with dermatomyositis by reducing itch and inflammation.
How similar studies have performed: Previous research has shown promising results with similar cannabinoid treatments, indicating potential for success in this area.
Where this research is happening
PHILADELPHIA, UNITED STATES
- UNIVERSITY OF PENNSYLVANIA — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WERTH, VICTORIA P — UNIVERSITY OF PENNSYLVANIA
- Study coordinator: WERTH, VICTORIA P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Pruritic Disorder